Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 36.

Bachmann, M F; Kündig, T M (2017). Allergen-specific immunotherapy: is it vaccination against toxins after all? Allergy, 72(1):13-23.

Hjálmsdóttir, Á; Wäckerle-Men, Y; Duda, A; Kündig, T M; Johansen, P (2016). Dosing intervals in intralymphatic immunotherapy. Clinical and Experimental Allergy, 46(3):504-507.

Freiberger, S N; Zehnder, M; Gafvelin, G; Grönlund, H; Kündig, T M; Johansen, P (2016). IgG4 but no IgG1 antibody production after intralymphatic immunotherapy with recombinant MAT-Feld1 in human. Allergy, 71(9):1366-1370.

Kündig, T M; Klimek, L; Schendzielorz, P; Renner, W A; Senti, G; Bachmann, M F (2015). Is the allergen really needed in allergy immunotherapy? Current Treatment Options in Allergy, 2:72-82.

Zaleska, A; Eiwegger, T; Soyer, O; van de Veen, W; Rhyner, C; Soyka, M B; Bekpen, C; Demiröz, D; Treis, A; Söllner, S; Palomares, O; Kwok, W W; Rose, H; Senti, G; Kündig, T M; Ozoren, N; Jutel, M; Akdis, C A; Crameri, R; Akdis, M (2014). Immune regulation by intralymphatic immunotherapy with modular allergen translocation MAT vaccine. Allergy, 69(9):1162-1170.

Uermösi, C; Zabel, F; Manolova, V; Bauer, M; Beerli, R R; Senti, G; Kündig, T M; Saudan, P; Bachmann, M F (2014). IgG-mediated down-regulation of IgE bound to mast cells: a potential novel mechanism of allergen-specific desensitization. Allergy, 69(3):338-347.

Klimek, L; Willers, J; Schendzielorz, P; Kündig, T M; Senti, G (2013). Immuntherapie der allergischen Rhinitis ohne Allergene? : Neue Möglichkeiten einer Immunmodulation durch Vakzinierung mittels „virus-like particles“ und CpG-Motiven. HNO, 61(10):826-833.

Mohanan, D; Gander, B; Kündig, T M; Johansen, P (2012). Encapsulation of antigen in poly(d,l-lactide-co-glycolide) microspheres protects from harmful effects of γ-irradiation as assessed in mice. European Journal of Pharmaceutics and Biopharmaceutics, 80(2):274-281.

von Moos, S; Johansen, P; Waeckerle-Men, Y; Mohanan, D; Senti, G; Häffner, A; Kündig, T M (2012). The contact sensitizer diphenylcyclopropenone has adjuvant properties in mice and potential application in epicutaneous immunotherapy. Allergy, 67(5):638-646.

Fettelschoss, A; Kistowska, M; LeibundGut-Landmann, S; Beer, H D; Johansen, P; Senti, G; Contassot, E; Bachmann, M F; French, L E; Oxenius, A; Kündig, T M (2011). Inflammasome activation and IL-1β target IL-1α for secretion as opposed to surface expression. Proceedings of the National Academy of Sciences of the United States of America, 108(44):18055-18060.

Johansen, P; Weiss, A; Bünter, A; Waeckerle-Men, Y; Fettelschoss, A; Odermatt, B; Kündig, T M (2011). Clemastine causes immune suppression through inhibition of extracellular signal-regulated kinase-dependent proinflammatory cytokines. Journal of Allergy and Clinical Immunology, 128(6):1286-1294.

Kündig, T M; Johansen, P; Senti, G (2011). Intralymphatic vaccination. In: Rappuoli, R; Bagnoli, F. Vaccine design: innovative approaches and novel strategies. Norfolk, UK: Caister Academic Press, 211-224.

Senti, G; von Moos, S; Kündig, T M (2011). Epicutaneous allergen administration: is this the future of allergen-specific immunotherapy? Allergy, 66(6):798-809.

Kündig, T M (2011). Immunotherapy concepts under investigation. Allergy, 66(s95):60-62.

Senti, G; Johansen, P; Kündig, T M (2011). Intralymphatic immunotherapy: from the rationale to human applications. In: Valenta, R; Coffman, R L. Vaccines against Allergies. Berlin Heidelberg: Springer, 71-84.

von Moos, S; Kündig, T M; Senti, G (2011). Novel administration routes for allergen-specific immunotherapy: a review of intralymphatic and epicutaneous allergen-specific immunotherapy. Immunology and Allergy Clinics of North America, 31(2):391-406.

Johansen, P; Fettelschoss, A; Amstutz, B; Selchow, P; Waeckerle-Men, Y; Keller, P; Deretic, V; Held, L; Kündig, T M; Böttger, E C; Sander, P (2011). Relief from zmp1-mediated arrest of phagosome maturation is associated with facilitated presentation and enhanced immunogenicity of mycobacterial antigens. Clinical and Vaccine Immunology : CVI, 18(6):907-913.

Johansen, P; Mohanan, D; Martínez-Gómez, J M; Kündig, T M; Gander, B (2010). Lympho-geographical concepts in vaccine delivery. Journal of Controlled Release, 148(1):56-62.

Mohanan, D; Slütter, B; Henriksen-Lacey, M; Jiskoot, W; Bouwstra, J A; Perrie, Y; Kündig, T M; Gander, B; Johansen, P (2010). Administration routes affect the quality of immune responses: A cross-sectional evaluation of particulate antigen-delivery systems. Journal of Controlled Release, 147(3):342-349.

Kündig, T M; Bachmann, M F (2010). Allergen-specific immunotherapy: Regulatory T cells or allergen-specific IgG? Human Vaccines, 6(8):673-675.

Tay, F; Kündig, T M; Senti, G (2010). Allergenspezifische Immuntherapie: Auf neuen Wegen in die Zukunft. Praxis, 99(21):1279-1284.

Uermösi, C; Beerli, R R; Bauer, M; Manolova, V; Dietmeier, K; Buser, R B; Kündig, T M; Saudan, P; Bachmann, M F (2010). Mechanisms of allergen-specific desensitization. Journal of Allergy and Clinical Immunology, 126(2):375-383.

Johansen, P; Wäckerle-Men, Y; Senti, G; Kündig, T M (2010). Nickel sensitisation in mice: a critical appraisal. Journal of Dermatological Science, 58(3):186-192.

Senti, G; Johansen, P; Kündig, T M (2009). Intralymphatic immunotherapy. Current Opinion in Allergy and Clinical Immunology, 9(6):537-43.

Senti, G; Graf, N; Haug, Susanne; Rüedi, N; von Moos, S; Sonderegger, T; Johansen, P; Kündig, T M (2009). Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy. Journal of Allergy and Clinical Immunology, 124(5):997-1002.

Senti, G; Johansen, P; Haug, Susanne; Bull, C; Gottschaller, C; Müller, P; Pfister, T; Maurer, P; Bachmann, M F; Graf, N; Kündig, T M (2009). Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial. Clinical and Experimental Allergy, 39(4):562-570.

Martínez-Gómez, J M; Johansen, P; Rose, H; Steiner, M; Senti, G; Rhyner, C; Crameri, R; Kündig, T M (2009). Targeting the MHC class II pathway of antigen presentation enhances immunogenicity and safety of allergen immunotherapy. Allergy, 64(1):172-178.

Smith, K A; Tam, V L; Wong, R M; Pagarigan, R R; Meisenburg, B L; Joea, D K; Liu, X; Sanders, C; Diamond, D; Kündig, T M; Qiu, Z; Bot, A (2009). Enhancing DNA vaccination by sequential injection of lymph nodes with plasmid vectors and peptides. Vaccine, 27(19):2603-2615.

Martínez-Gómez, J M; Johansen, P; Erdmann, I; Senti, G; Crameri, R; Kündig, T M (2009). Intralymphatic injections as a new administration route for allergen-specific immunotherapy. International Archives of Allergy and Immunology, 150(1):59-65.

Mantinez-Gomez, J M; Johansen, P; Erdmann, I; Senti, G; Crameri, R; Kündig, T M (2009). Intralymphatic injections as a new prospective administration route for allergen-specific immunotherapy. International Archives of Allergy and Immunology, 150(1):59-65.

Smith, K A; Meisenburg, B L; Tam, V L; Pagarigan, R R; Wong, R; Joea, D K; Lantzy, L; Carrillo, M A; Gross, T M; Malyankar, U M; Chiang, C S; Da Silva, D M; Kündig, T M; Kast, W M; Qiu, Z; Bot, A (2009). Lymph node-targeted immunotherapy mediates potent immunity resulting in regression of isolated or metastatic human papillomavirus-transformed tumors. Clinical Cancer Research, 15(19):6167-6176.

Kündig, T M; Johansen, P; Senti, S (2009). Rationale and applications of allergen intralymphatic immunotherapy. In: Valenta, R; Coffman, R. Current Topics in Microbiology and Immunology. Berlin: Springer, ?.

Senti, G; Prinz Vavricka, B M; Erdmann, I; Diaz, M I; Markus, R; McCormack, S J; Simard, J J; Wüthrich, B; Crameri, R; Graf, N; Johansen, P; Kündig, T M (2008). Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. Proceedings of the National Academy of Sciences of the United States of America (PNAS), 105(46):17908-17912.

Martínez Gómez, J M; Csaba, N; Fischer, S; Sichelstiel, A; Kündig, T M; Gander, B; Johansen, P (2008). Surface coating of PLGA microparticles with protamine enhances their immunological performance through facilitated phagocytosis. Journal of Controlled Release, 130(2):161-167.

Johansen, P; Storni, T; Rettig, L; Qiu, Z; Der-Sarkissian, A; Smith, K A; Manolova, V; Lang, K S; Senti, G; Müllhaupt, B; Gerlach, T; Speck, R F; Bot, A M; Kündig, T M (2008). Antigen kinetics determines immune reactivity. Proceedings of the National Academy of Sciences of the United States of America (PNAS), 105(13):5189-5194.

Johansen, P; Senti, G; Maria Martínez Gómez, J; Kündig, T M (2008). Medication with antihistamines impairs allergen-specific immunotherapy in mice. Clinical and Experimental Allergy, 38(3):512-519.

This list was generated on Sat Sep 23 08:28:15 2017 CEST.